Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 29.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 26,646 shares of the biopharmaceutical company’s stock after buying an additional 6,031 shares during the period. Alnylam Pharmaceuticals comprises about 0.9% of EFG Asset Management North America Corp.’s portfolio, making the stock its 22nd largest holding. EFG Asset Management North America Corp.’s holdings in Alnylam Pharmaceuticals were worth $6,276,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Larson Financial Group LLC boosted its stake in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 73 shares during the last quarter. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $33,000. True Wealth Design LLC grew its holdings in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 153 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $35,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $45,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 in the last ninety days. 1.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ALNY has been the subject of a number of recent research reports. Sanford C. Bernstein cut their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Wells Fargo & Company increased their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a report on Friday. Chardan Capital reissued a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday. HC Wainwright raised their target price on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Finally, Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $312.30.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $290.70 on Tuesday. The stock’s 50-day moving average price is $257.81 and its 200 day moving average price is $260.02. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market cap of $37.63 billion, a price-to-earnings ratio of -133.96 and a beta of 0.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.